In a randomized phase III trial with stage IV or recurrent NSCLC, nivolumab as first-line therapy was found not superior to chemotherapy in PFS or response rate in patients whose tumor had PD-L1 expression of ≥5%. This evidence concerns the gene CD274 and neoplasm.